Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Neoplasms 2Hematologic Diseases 2Thrombocytosis 1Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer 1Polycythemia 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Hemorrhagic Disorders 1EGFR Mutated EGFR TKI Naive Metastatic NSCLC 1Bone Marrow Diseases 1Blood Platelet Disorders 1Blood Coagulation Disorders 1

Interventions

dacetuzumab 2Bortezomib 2sonidegib 1ruxolitinib 1ficlatuzumab 1Vorinostat 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Lenalidomide 1Erlotinib Hydrochloride 1Dexamethasone 1Calcium Dobesilate 1ARQ531 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemorrhagic Disorders × N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide × Clear all
NCT01998828 2020-04-20

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Sierra Oncology LLC - a GSK company

Phase 2 Terminated
39 enrolled
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡